belzutifan
FDA Approves Welireg for Pheochromocytoma or Paraganglioma
The FDA approved Welireg for patients aged 12 years and older with locally advanced, unresectable, or metastatic ...
MAY 21, 2025
FDA Approves Welireg for Tumors Associated With VHL Disease
The FDA approved belzutifan (Welireg, Merck), a hypoxia-inducible factor inhibitor, for adults with von ...
AUGUST 27, 2021
Load more